The ongoing clinical trials assessing combined treatments with covalent KRAG G12C inhibitors plus other anticancer drugs will elucidate effective therapeutic strategies for KRAS-mutated NSCLC patients (Table 1). This evidence concerns the gene KRAS and non-small cell lung carcinoma.